Certara (NASDAQ:CERT) Issues Earnings Results, Misses Estimates By $0.01 EPS

Certara (NASDAQ:CERT - Get Free Report) issued its quarterly earnings results on Wednesday. The company reported $0.12 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.13 by ($0.01), Zacks reports. Certara had a positive return on equity of 3.43% and a negative net margin of 8.34%. The business had revenue of $100.36 million during the quarter, compared to analysts' expectations of $99.13 million. Certara updated its FY 2025 guidance to 0.420-0.460 EPS.

Certara Price Performance

Shares of Certara stock traded down $0.42 during trading hours on Friday, reaching $11.98. 1,956,342 shares of the company's stock were exchanged, compared to its average volume of 1,314,086. Certara has a 1 year low of $9.41 and a 1 year high of $19.87. The company has a market capitalization of $1.93 billion, a P/E ratio of -59.90, a price-to-earnings-growth ratio of 9.29 and a beta of 1.57. The business has a fifty day moving average of $12.45 and a two-hundred day moving average of $11.63. The company has a quick ratio of 2.86, a current ratio of 2.86 and a debt-to-equity ratio of 0.28.

Analysts Set New Price Targets

CERT has been the subject of several recent analyst reports. TD Cowen initiated coverage on shares of Certara in a research note on Thursday. They set a "buy" rating and a $16.00 price objective for the company. William Blair reaffirmed a "market perform" rating on shares of Certara in a research note on Thursday. Stephens reaffirmed an "overweight" rating and set a $17.00 price objective on shares of Certara in a research note on Thursday. Robert W. Baird dropped their price objective on shares of Certara from $18.00 to $13.00 and set a "neutral" rating for the company in a research note on Tuesday, November 5th. Finally, Barclays boosted their target price on Certara from $12.00 to $13.00 and gave the company an "equal weight" rating in a research report on Friday. Four analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $15.83.

Remove Ads

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.